LEVERKUSEN, Germany, Nov. 13, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a chief world Promise Analysis, Building, and Production Group (CRDMO), introduced that it is going to toughen its drug product (DP) features on the corporate’s facility in Leverkusen, Germany, with a untouched sterile filling series for prefilled syringes (PFS) the use of isolator generation.
Building of the untouched series will optimize the design of the Leverkusen facility’s production sequence to be extra environment friendly for multi-product CRDMO virtue. The untouched series, with its capacity to deal with more than one syringe sizes (1 ml, 2.25 ml, and three ml) at a filling charge of as much as 400 syringes according to slight, permits versatile GMP manufacturing of no less than 17 million syringes each and every pace. This might be along with the prevailing sterile filling and freeze-drying series that has an annual capability of roughly ten million doses. Building is scheduled to start lately, with the function of accomplishing GMP compliance via 2026.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “The increased capacity in Germany will allow us to continue to meet growing client demand for DP services, especially for prefilled syringes. Such investments further demonstrate our commitment to the Global Dual Sourcing strategy that ensures materials can be sourced and products manufactured at multiple sites within the company’s global network. As a trusted partner to global healthcare companies and a significant contributor to the local community, we are dedicated to providing efficient and cost-effective processes that enable our clients to bring breakthrough therapies to patients.”
About WuXi Biologics
WuXi Biologics (secure code: 2269.HK) is a chief world Promise Analysis, Building and Production Group (CRDMO) providing end-to-end answers that permit companions to find, build and assemble biologics – from thought to commercialization – for the advantage of sufferers international.
With over 12,000 professional staff in China, the USA, Eire, Germany and Singapore, WuXi Biologics leverages its applied sciences and experience to serve shoppers with environment friendly and cost-effective biologics discovery, building and production answers. As of June 30, 2024, WuXi Biologics is supporting 742 built-in shopper initiatives, together with 16 in business production (with the exception of COVID CMO and non-COVID dormant CMO initiatives).
WuXi Biologics perspectives Environmental, Social, and Governance (ESG) tasks as an integral trait of our ethos and trade technique, and we try to turn into an ESG chief within the biologics CRDMO sector. Our amenities virtue next-generation biomanufacturing applied sciences and clean-energy resources. We’ve additionally established an ESG committee led via our CEO to influence the great ESG technique and its implementation, bettering our constancy to sustainability.
For more info about WuXi Biologics, please discuss with: www.wuxibiologics.com.
Contacts
Media
[email protected]
Industry
[email protected]
SOURCE WuXi Biologics
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Virtual Media
Retailers
270k+
Reporters
Opted In
